Experimental evidence for a neural origin of Ewing's sarcoma of bone
- PMID: 3035930
- PMCID: PMC1899764
Experimental evidence for a neural origin of Ewing's sarcoma of bone
Abstract
The histogenesis of Ewing's sarcoma remains unknown. Recent studies have suggested a relationship to an unusual form of childhood neural tumor, often termed peripheral neuroepithelioma or primitive neuroectodermal tumor. Five Ewing's sarcoma tumor cell lines were studied for evidence of a neural phenotype. Under normal culture conditions, no morphologic evidence of neural differentiation was detected. Treatment with retinoic acid, an agent known to induce marked neural differentiation in neuroblastoma, had no demonstrable effect. Treatment with either cyclic AMP or TPA, in contrast, induced pronounced morphologic evidence of neural differentiation. Cells developed elongate processes with varicosities by phase-contrast microscopy; filaments, microtubules, and uraniffin-positive dense core granules were present by electron microscopy. Three neural markers (NSE, NFTP, and cholinesterase) were absent or barely detectable in untreated cells, but became abundant after treatment. These results provide convincing evidence for a neural histogenesis of Ewing's sarcoma. They also suggest a close relationship between Ewing's sarcoma and peripheral neural tumors, including the chest wall tumor described by Askin, but only a distant relationship to neuroblastoma.
Similar articles
-
Small round blue cell sarcoma of bone mimicking atypical Ewing's sarcoma with neuroectodermal features. An analysis of five cases with immunohistochemical and electron microscopic support.Cancer. 1987 Oct 1;60(7):1570-82. doi: 10.1002/1097-0142(19871001)60:7<1570::aid-cncr2820600727>3.0.co;2-r. Cancer. 1987. PMID: 3113717
-
Neurogenic potential of Ewing's sarcoma cells.Virchows Arch. 1997 Jan;430(1):41-6. doi: 10.1007/BF01008015. Virchows Arch. 1997. PMID: 9037314
-
Dynamic model of differentiation in Ewing's sarcoma cells. Comparative analysis of morphologic, immunocytochemical, and oncogene expression parameters.Lab Invest. 1992 Feb;66(2):143-51. Lab Invest. 1992. PMID: 1310513
-
[Pathology of Ewing sarcoma].Pathologe. 1996 Jan;17(1):6-17. doi: 10.1007/s002920050129. Pathologe. 1996. PMID: 8685098 Review. German.
-
Ewing's sarcoma.Radiol Clin North Am. 1993 Mar;31(2):325-37. Radiol Clin North Am. 1993. PMID: 8446752 Review.
Cited by
-
Pathobiologic markers of the ewing sarcoma family of tumors: state of the art and prediction of behaviour.Sarcoma. 2011;2011:856190. doi: 10.1155/2011/856190. Epub 2010 Oct 14. Sarcoma. 2011. PMID: 20981347 Free PMC article.
-
Ewing sarcoma from molecular biology to the clinic.Front Cell Dev Biol. 2023 Sep 11;11:1248753. doi: 10.3389/fcell.2023.1248753. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37752913 Free PMC article. Review.
-
Progress in the molecular biology of ewing tumors.Sarcoma. 1998;2(1):3-17. doi: 10.1080/13577149878109. Sarcoma. 1998. PMID: 18521227 Free PMC article.
-
Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma.Mol Biol Cell. 2014 Sep 15;25(18):2695-709. doi: 10.1091/mbc.E14-01-0007. Epub 2014 Jul 23. Mol Biol Cell. 2014. PMID: 25057021 Free PMC article.
-
Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma.Oncotarget. 2016 Jun 7;7(23):34860-80. doi: 10.18632/oncotarget.8992. Oncotarget. 2016. PMID: 27145455 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical